<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04206644</url>
  </required_header>
  <id_info>
    <org_study_id>35RC19_30043_SCLERO JAK</org_study_id>
    <nct_id>NCT04206644</nct_id>
  </id_info>
  <brief_title>Systemic Sclerosis and Jak Inhibitors : Emphasis on Macrophages</brief_title>
  <acronym>SCLERO JAK</acronym>
  <official_title>Systemic Sclerosis and Jak Inhibitors : Emphasis on Macrophages</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Sclero-JAK project aims to assess the impact of a JAK1/2 inhibitor (ruxolitinib) on&#xD;
      activation states of monocytes-derived macrophages (MDM) from systemic sclerosis (SSc)&#xD;
      patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systemic sclerosis is a fibrotic and inflammatory chronic autoimmune disorder with no disease&#xD;
      modifiying drug available to date. JAK inhibitors may represent a relevant therapeutic&#xD;
      candidate for this disease;&#xD;
&#xD;
      The primary objective of this study is to characterize the impact of Ruxolitinib (a JAK ½&#xD;
      inhibitor) on the prof-fibrotic properties of MDM from SSc patients in vitro.&#xD;
&#xD;
      The primary outcome will be the concentration of CCL18 evaluate by ELISA in the condition&#xD;
      media of MDM from SSc patients pre treated or not in vitro by ruxolitinib.&#xD;
&#xD;
      The secondary objectives :&#xD;
&#xD;
        1. To characterize the impact of ruxolitinib on other pro-inflammatory or pro-fibrotic&#xD;
           cytokines&#xD;
&#xD;
        2. To characterize the impact of ruxolitinib on membrane expression of macrophagic&#xD;
           polarization markers of MDM from SSc patients&#xD;
&#xD;
        3. To evaluate the impact of ruxolitinib on the phenotype of MDM from healthy donors&#xD;
           exposed in vitro to the serum of SSc patients.&#xD;
&#xD;
        4. To determine the variability of the effects of ruxolitinib on MDM of SSc patients&#xD;
           depending on key clinical characteristics (diffuse versus limited SSc, patients with or&#xD;
           without Interstitial Lung disease ILD)&#xD;
&#xD;
      The secondary outcomes :&#xD;
&#xD;
        1. ELISA of the following cytokine evaluated in the condition media of SSc MDM pre-treated&#xD;
           or not with ruxolitinib : PDGFbb, IL-6, CXCL10, CXCL4&#xD;
&#xD;
        2. Membrane expression (flow cytometry) of the following markers expressed by SSc MDM&#xD;
           pre-treated or not with ruxoltinib : CD204, CD206, CD163, CD86, CMHII, TLR4.&#xD;
&#xD;
        3. Evaluation of the same cytokines and membrane markers in MDM from HD exposed to serum&#xD;
           media of SSc patients.&#xD;
&#xD;
        4. Variation of the effect of ruxolitinib on the primary outcome (CCL18 secreted in the&#xD;
           condition media of MDM from SSc patients) in sub groups depending on the following&#xD;
           characteristics :&#xD;
&#xD;
             -  Auto antibodies (anticentromere, antitopoisomerase, anti RNA polymerase III or&#xD;
                none)&#xD;
&#xD;
             -  modified Rodnan skin score&#xD;
&#xD;
             -  Digital ulcers (current or past)&#xD;
&#xD;
             -  Pulmonary involvement (Interstitial Lung disease on CT scan)&#xD;
&#xD;
             -  Heart involvement (Pulmonary arterial hypertension on echocardiography)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2021</start_date>
  <completion_date type="Anticipated">February 21, 2027</completion_date>
  <primary_completion_date type="Anticipated">January 21, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of CCL18 in the condition media of MDM from SSc patients</measure>
    <time_frame>through study completion, an average of 4 year</time_frame>
    <description>at the end of the study</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>Systemic sclerosis patients</arm_group_label>
    <description>SSc patients according to the ACR/EULAR 2013 classification criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy donors</arm_group_label>
    <description>HD healthy donors from EFS (Etablissement Français du sang)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LUPUS Patiets</arm_group_label>
    <description>Lupus patients according to the ACR 2019 classification criteria</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>biological analysis</intervention_name>
    <description>biological analysis of the Concentration of CCL18</description>
    <arm_group_label>Healthy donors</arm_group_label>
    <arm_group_label>Systemic sclerosis patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with systemic sclerosis according to the ACR/EULAR 2013 classification criteria&#xD;
        for systemic sclerosis&#xD;
&#xD;
        or Lupus patients according to the ACR 2019 classification criteria&#xD;
&#xD;
        or healthy donors&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with systemic sclerosis according to the ACR/EULAR 2013 classification&#xD;
             criteria for systemic sclerosis or Patients with systemic lupus according to the&#xD;
             ACR2019 classification criteria for systemic lupus&#xD;
&#xD;
          -  with informed consent for participation to the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients unable to consent&#xD;
&#xD;
          -  patients with anemia inferior to 7g/dL&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Patrick JEGO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristell COAT</last_name>
    <phone>299282555</phone>
    <phone_ext>+33</phone_ext>
    <email>kristell.coat@chu-rennes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Direction de la recherche</last_name>
    <phone>299282555</phone>
    <phone_ext>+33</phone_ext>
    <email>dri@chu-rennes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rennes University Hospital</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick JEGO, PH-PD</last_name>
    </contact>
    <investigator>
      <last_name>Patrick JEGO, PH-PD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 18, 2019</study_first_submitted>
  <study_first_submitted_qc>December 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2019</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Systemic sclerosis</keyword>
  <keyword>macrophage</keyword>
  <keyword>ruxolitinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

